Medtronic Stock News

Visa has a resilient business, a solid competitive edge, and attractive avenues for growth. Medtronic is performing well, and new product launches are providing a potentially long-lasting tailwind.

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%), and CHRW (+61.22%) delivered strong double-digit returns. Dividend growth for the Aristocrats slowed to 5.52% in 2025, down from 5.78% in 2024, with 68 of 69 raising payouts.

Bristol Myers Squibb is a pharmaceutical giant with a solid dividend history. Medtronic is a high-yield medical device maker that's nearing Dividend King status.

Explore the exciting world of Medtronic (MDT 0.38%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Intuitive Surgical is a first-to-market leader in the field of surgical robotics. Medtronic is making headway with its own robot-assisted surgical system.

This drug company offers a decent balance of risk and reward, with a 4.6% yield and a payout ratio comfortably below 100%. This medical device company has a 2.9% yield and is nearing Dividend King status.

When inflation drops, as we saw in the November consumer price index report, the Federal Reserve typically continues to cut interest rates, making fixed-income alternatives less attractive.

MiniMed Group, Inc., a Medtronic subsidiary, is targeting an IPO to fund growth and working capital amid diabetes device market expansion. MMED is well-positioned in automated insulin delivery, boasting an integrated product stack, strong recurring revenue, and international reach. Financials show rising revenue and gross profit, but operating leverage remains limited due to high R&D and pendin...